Validation of Novel Prognostic Biomarkers for Early-Stage Clear-Cell, Endometrioid and Mucinous Ovarian Carcinomas Using Immunohistochemistry

Validation of Novel Prognostic Biomarkers for Early-Stage Clear-Cell, Endometrioid and Mucinous Ovarian Carcinomas Using Immunohistochemistry

Early-stage (I and II) ovarian carcinoma patients generally have good prognosis. Yet, some patients die earlier than expected. Thus, it is important to stratify early-stage patients into risk groups to identify those in need of more aggressive treatment regimens. The prognostic value of 29 histotype...

Full description

Bibliographic Details
Main Authors: Hanna Engqvist, Toshima Z. Parris, Anikó Kovács, Elisabeth Werner Rönnerman, Karin Sundfeldt, Per Karlsson, Khalil Helou
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-02-01
Series:Frontiers in Oncology
Subjects:
clear-cell ovarian carcinoma
endometrioid ovarian carcinoma
mucinous ovarian carcinoma
histotype-specific prognostic biomarkers
immunohistochemistry
early-stage ovarian carcinoma
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.00162/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.00162/full

Similar Items